Selecta chooses Takashi Kei Kishimoto for CSO
This article was originally published in Scrip
Executive Summary
Selecta Biosciences, a biopharmaceutical company developing novel targeted vaccines and immunotherapies, has appointed Dr Takashi Kei Kishimoto chief scientific officer reporting to Dr Werner Cautreels, Selecta's CEO. Dr Kishimoto most recently served as vice-president of research at Momenta Pharmaceuticals, where he led a team advancing novel and complex generic products for inflammation, oncology and cardiovascular disease.